References
- Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasmino-gen system. J Clin Invest 1995; 96: 2534–8.
- Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin acti-vable fibrinolysis inhibitor. J Biol Chem 1995; 270: 1477–84.
- Bajzar L, Morser J, Nesheim ME. TAFI, or plasma procarboxypeptidase B, couples the coa-gulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603–8.
- Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477–82.
- Wang W, Boffa MB, Bajzar L, Walker JB, Neisheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176–81.
- Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-activable fibri-nolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosilation, throm-bin/thrombomodulin dependent activation, ther-mal stability and enzymatic properties. J Biol Chem 1998; 273: 12135–9.
- Marx PF, Hackeng TM, Dawson PE, Griffin JH, Meijers JCM, Bouma BN. Inactivation of active thrombin activatable fibrinolysis inhibitor takes places by a process that involves conformational instability rather than proteolytic cleavage. J Biol Chem 2000; 275: 12410–5.
- Marx PF, Dawson PE, Bouma BN, Meijers JCM. Plasmin mediated activation and inactivation of thrombin activatable fibrinolysis inhibitor. Bio-chemistry 2002; 41: 6688–96.
- Antovic J, Schulman S, Eelde A, Blomback M. Total thrombin activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A. Haemophilia 2001; 7: 557–60.
- Mosnier LO, von dem Borne K, Meijers JCM, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829–35.
- Chetaille P, Alessi MC, Kouassi D, Morange I, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000; 83: 902 — 5.
- Schatteman KA, Goosens FJ, Scharpe SS, Neels HM, Hendriks DF. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade in human plasma. Clin Chem 1999; 45: 807–13.
- Broze GJ, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots form hemophilic plasma. Blood 1996; 88: 3815— 23.
- Mosnier LO, Lisman T, van der Berg M, Nieuwenhuis HK, Meijers JCM, Bouma BN. The defective down regulation of fibrinolysis in hemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001; 86: 1035–9.
- Keultars IM, Hamulyak K, Hemker HC, Beguin S. The effect of DDAVP infusion on throm-bin generation in platelet rich plasma of von Willebrand type 1 and mild hemophilia A patients. Thromb Haemost 2000; 84: 638–42.
- Von dem Borne PAK, Bajzar L, Meijers JCM, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in thrombin-activatable fibrinolysis inhibitor-dependent inhibi-tion of fibrinolysis. J Clin Invest 1997; 99: 2323–7.
- Ramstrom G, Blombäck M. Tooth extractions in hemophiliacs. Int J Oral Surg 1975; 4: 1–17.
- Piot B, Sigaud-Fiks M, Huet P, Fressinaud E, Trossaert M, Mercier J. Management of dental extractions in patients with bleeding disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93: 247–50.
- Antovic JP, Antovic A, Blombäck M. Does recombinant factor FVIIa, apart from overall hemostasis regulate TAFI dependent fibrinolysis in factor VIII deficient plasma and in hemophilia A patients? Blood 2003; 102: 796a Abstract No. 2948.
- Leurs J, Wissing BM, Nerme V, Schatteman K, Björquist P, Hendriks D. Different mechanism contribute to the biphasic pattern of carboxypep-tidase U (TAFIa) generation during in vitro clot lysis in human plasma. Thromb Haemost 2003; 89: 264— 71.
- Greenfield RS, Antovic J, An J, Blombäck M, An SSA. Elevated TAFIa/ai antigen levels are a marker for hyperfibrinolytic state in hemophilia patients. Thrombos Haemost 2002 Suppl 16th International Congress on Fibrinolysis, Munich, Germany; S49
- Meijers JCM, Oudijk EJD, Mosnier LO, Bos R, Bouma BN, Nieuwenhuis HK, Fijnheer R. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukemia. Br J Haematol 2000; 108: 518–23.